Chitosan and its derivatives as the carrier for intranasal drug delivery

Asian Journal of Pharmaceutical Sciences

Volumn 7, Issue 6, 2012, Pages 352-363

  Ding, Jiaojiao ^a   Na, Lidong ^a   Mao, Shirui ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Application; Chitosan; Derivatives; Influencing factors; Intranasal

Indexed keywords

ANTHRAX VACCINE; CARBOXYLESTERASE; CHITOSAN; CHITOSAN DERIVATIVE; CYTOCHROME P450; DRUG CARRIER; GLUTATHIONE TRANSFERASE; INSULIN; ISOENZYME; LIPOSOME; MICROSPHERE; MILNACIPRAN; MORPHINE; NANOPARTICLE; NOSE SPRAY; TETRAMETHYLPYRAZINE; VENLAFAXINE;

ABSORPTION; ANTIBODY RESPONSE; ANTIDEPRESSANT ACTIVITY; ANTIMICROBIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BIOCOMPATIBILITY; BIODEGRADABILITY; BLOOD BRAIN BARRIER; CELL MEMBRANE PERMEABILITY; DEACETYLATION; DENSITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG HALF LIFE; DRUG SOLUTION; DRUG TARGETING; DRY POWDER; ELECTRIC RESISTANCE; ENCAPSULATION; ENZYMATIC DEGRADATION; GEL; GENE TARGETING; IMMUNE RESPONSE; IMMUNOGENICITY; INTRANASAL DRUG ADMINISTRATION; MOLECULAR WEIGHT; MUCOADHESION; MUCOCILIARY CLEARANCE; NONHUMAN; NOSE CAVITY; OLFACTORY EPITHELIUM; OLFACTORY RECEPTOR; PARTICLE SIZE; PH; SYSTEMIC THERAPY; VACCINATION;

EID: 84877029379     PISSN: 18180876     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (121)

1. Costantino HR, Illum L, Brandt G, et al. Intranasal delivery: physicochemical and therapeutic aspects. Int J Pharm. 2007, 337:1-24.
2. Illum L. Nasal drug delivery-possibilities, problems and solutions. J Control Release. 2003, 87: 187-198.
3. Corbo DC, Liu JC, Chien YW. Drug absorption through mucosal membranes: effect of mucosal route and penetrant hydrophilicity. Pharm Res. 1989, 6:848-852
4. Vyas1 TK, Shahiwala A, Marathe S, et al. Intranasal Drug Delivery for Brain Targeting. Curr Drug Deliv. 2005, 2: 165-175.
5. Illum L. Nasal drug delivery-Recent developments and future prospects. J Control Release. 2012, 161: 254-263.
6. Talegaonkarand S. Mishra P. Intranasal delivery: An approach to bypass the blood brain barrier. Indian J Pharmacol. 2004, 36: 140-147.
7. Ugwoke MI, Agu RU, Verbeke N, et al. Nasal mucoadhesive drug delivery: Background, applications, trends and future perspectives. Adv Drug Deliv Rev. 2005, 57: 1640-1665.
8. Mygind N. Dahl R. Anatomy, physiology and function of the nasal cavities in health and disease. Adv Drug Deliv Rev, 1998, 29: 3-12.
9. Patel P, Pachouriya R, Sudeesh M, et al. An ornamental mucoadhesive particulate drug delivery system for nasal route: A review. J Pharm Res. 2010, 3: 1788-1792.
10. Chugh Y, Kapoor P, Kapoor A. Intranasal drug delivery: a novel approach. Indian J Otolaryngol. 2009, 61: 90-94.
11. Perry C, Sim AM, Feron F, et al. Olfactory neural cells: an untapped diagnostic and therapeutic resource. Laryngoscope. 2002, 112: 603-607.
12. Harding SE. Trends in muco-adhesive analysis. Trends Food Sci Tech. 2006, 17: 255-262.
13. Madara JL. Modulation of tight junctional permeability. Adv Drug Del Rev. 2000, 41: 251-253.
14. Davisand SS, Illum L. Absorption enhancers for nasal drug delivery. Clinpharmacokinet. 2003, 42: 1107-1128.
15. Onishi H, Machida Y. Biodegradation and distribution of water-soluble chitosan in mice. Biomaterials. 1999, 20: 175-182.
16. Rao SB, Sharma CP. Use of chitosan as a biomaterial: studies on its safety and hemostatic potential. J Biomed Mater Res. 1997, 34: 21-28.
17. Paul W, Garside CP. Chitosan, a drug carrier for the 21st century: A review. STP Pharm Sci. 2000, 10:5-22.
18. Lubben IM, Verhoef JC, Borchard G, et al. Chitosan and its derivatives in mucosal drug and vaccine delivery, Eur J Pharm Sci. 2001, 14: 201-207.
19. Soane RJ, Frier M, Perkins AC, et al. Evaluation of clearance characteristics of bioadhesive systems in humans. Int J Pharm. 1999, 78: 55-65.
20. Schipper NGM, Olsson S, Hoostraate AJ, et al. Chitosan as absorption enhancers for poorly absorbable drugs 2: mechanism of absorption enhancement. Pharm Res. 1997, 14: 923-929.
21. Issa MM, Koping-Hoggard M, Artursson P. Chitosan and the mucosal delivery of biotechnology drugs. Drug Discov Today. 2005, 2: 1-6.
22. Soane RJ, Frier M, Perkins AC, et al. Evaluation of clearance characteristics of bioadhesive systems in humans. Int J Pharm. 1999, 78: 55-65.
23. Ranaldi G, Marigliano I, Vespignani I. et al. The effect of chitosan and other polycations on tight junction permeability in the human intestinal Caco-2 cell line. JNutrBiochem. 2002, 13:157-167.
24. Smith JM, Dornish M, Wood EJ. Involvement of protein kinase C in chitosan glutamate-mediated tight junction disruption. Biomaterials. 2005, 26:3269-3276.
25. Yeh TH, Hsu LW, Tseng MT. et al. Mechanism and consequence of chitosan-mediated reversible epithelial tight junction opening. Biomaterials. 2011, 32: 6164-6173.
26. Aspden TJ, Illum L, Skaugrud Ø. Chitosan as a nasal delivery system: evaluation of insulin absorption enhancement and effect on nasal membrane integrity using rat models. Eur J Pharm Sci. 1996, 4: 23-31.
27. Costantino, HR, Sileno AP, Johnson PH. Pharmacokinetic attributes of intranasal delivery: case studies and new opportunities. Drug Deliv. 2005, 3: 8-11.
28. Illum L, Watts P, Fisher A, et al. Intranasal delivery of morphine. J PharmacolExpTher. 2002, 301: 391-400.
29. Mei D, Mao S, Sun W, et al. Effect of chitosan structure properties and molecular weight on the intranasal absorption of tetramethylpyrazine phosphate in rats. Eur J Pharm Biopharm. 2008, 70:874-881.
30. Inagaki M, akakura YS, Itoh J, et al. Macromolecular permeability of the tightjunction of the human nasal mucosa. Rhinology. 1985, 23: 213-221.
31. Sinswatand P. Tengamnuay P. Enhancing effect of chitosan on nasal absorption of salmon calcitonin in rats: comparison with hydroxypropyl-and dimethyl-β-cyclodextrins. Int J Pharm. 2003, 257:15-22.
32. Takeuchi H, Yamamoto H, Kawashima Y. Mucoadhesivenanoparticulate systems for peptide drug delivery. Adv Drug Deliv Rev. 2001, 47:39-54.
33. Fernández-Urrusuno R, Calvo P, Remuñán-López C J, et al. Enhancement of nasal absorption of insulin using chitosan nanoparticles. Pharm Res. 1999, 16:1576-1581.
34. Vyas TK, Shahiwala A, Marathe S, et al. Intranasal drug delivery for brain targeting. Curr Drug Deliv. 2005, 2: 165-175.
35. Haque S, Shadab M, Fazil M, et al. Venlafaxine loaded chitosan NPs for brain targeting: Pharmacokinetic and pharmacodynamic evaluation. CarbohydPolym. 2012, 89:72-29.
36. Uchida M, Katoh T, Mori M, et al. Intranasal Administration of Milnacipran in Rats: Evaluation of the Transport of Drugs to the Systemic Circulation and Central Nervous System and the Pharmacological Effect. Biol Pharm Bull. 2011, 34: 740-747.
37. Illum L, Jabbal-Gill I, Hinchcliffe M, et al. Chitosan as a novel nasal delivery system for vaccines. Adv Drug Deliv Rev. 2001,51:81-96.
38. Arca HÇ. Günbeyaz M, Şenel S. Chitosan-based systems for the delivery of vaccine antigens. Expert Rev Vaccines. 2009, 8:937-953.
39. Neutraand MR, Kozlowski PA. Mucosal vaccines: the promise and the challenge. Nat Rev Immunol. 2006,6:148-158.
40. Lubben IM, Verhoef JC, Borchard G, et al. Chitosan and its derivatives in mucosal drug and vaccine delivery. Eur J Pharm Sci. 2001, 14: 201-207.
41. Kumar M, Behera A K, Lockey RF, et al. Intranasal gene transfer by chitosan-DNA nanospheres protects BALB/c mice against acute respiratory syncytial virus infection. Hum Gene Ther. 2002,13:1415-1425.
42. Raghuwanshi D, Mishra V, Das D, et al. Dendritic Cell Targeted ChitosanNanoparticles for Nasal DNA Immunization against SARS CoV Nucleocapsid Protein. Mol Pharmaceut. 2012, 9: 946-956.
43. Mao HQ, Roy K, Troung-Le VL, et al. Chitosan-DNA nanoparticles as gene carriers: synthesis, characterization and transfection efficiency. J Control Release. 2001,70:399-421.
44. Jiang L, Qian F, He X, et al. Novel chitosan derivative nanoparticles enhance the immunogenicity of a DNA vaccine encoding hepatitis B virus core antigen in mice. J Gene Med. 2007,9:253-264.
45. Khatri K, Goyal AK, Gupta PN, et al. Plasmid DNA loaded chitosan nanoparticles for nasal mucosal immunization against hepatitis B. Int J Pharm. 2008, 354:235-241.
46. Xu W, Shen Y, Jiang Z, et al. Intranasal delivery of chitosan-DNA vaccine generates mucosal SIgA and anti-CVB3 protection. Vaccine. 2004, 22:3603-3612.
47. Charlton S, Jones N S, Davis SS, et al. Distribution and clearance of bioadhesive formulations from the olfactory region in man: Effect of polymer type and nasal delivery device. Eur J Pharm Sci. 2007, 30:295-302.
48. Yu SY, Zhao Y, Wu FL, et al. Nasal insulin delivery in the chitosan solution:in vitro and in vivo studies. Int J Pharm. 2004, 281: 11-23.
49. Zaki N, Awad G, Mortada N, et al. Rapid-onset intranasal delivery of metoclopramide hydrochloride:: Part I. Influence of formulation variables on drug absorption in anesthetized rats. Int J Pharm. 2006, 327:89-96.
50. Amidi M, Mastrobattista E, Jiskoot W, et al. Chitosan-based delivery systems for protein therapeutics and antigens. Adv Drug Deliv Rev. 2010, 62:59-82.
51. Nokhodchi A, Tailor A. In situ cross-linking of sodium alginate with calcium and aluminum ions to sustain the release of theophilline from polymeric matrices.Farmaco. 2004, 59: 999-1004.
52. Varshosaz J, Sadrai H, Heidari A. Nasal delivery of insulin using bioadhesive CH gels. Drug Deliv. 2006, 13: 31-8.
53. Ruel-Gariépy E, Leroux JC. In situ-forming hydrogels-review oftemperature-sensitive systems. Eur J Pharm Biopharm. 2004, 58:409-426.
54. H.J. Cho, P. Balakrishnan, E.K. Park, K.W. Song, S.S. Hong, T.Y. Jang, K.S. Kim, S.J. Chung, C.K. Shim, and D.D. Kim. Poloxamer/cyclodextrin/chitosan-based thermoreversible gel for intranasal delivery of fexofenadine hydrochloride. J Pharm Sci. 2011,100:681-691.
55. Khan S, Patil K, Bobade N, et al. Formulation of intranasal mucoadhesive temperature-mediated in situ gel containing ropinirole and evaluation of brain targeting efficiency in rats. J Drug Target. 2010,18:223-234.
56. Wu J, Wei W, Wang LY, et al. A thermosensitive hydrogel based on quaternized chitosan and poly (ethylene glycol) for nasal drug delivery system.Biomaterials. 2007, 28: 2220-2232.
57. Ishikawa F, Murano M, Hiraishi M, et al. Insoluble powder formulation as an effective nasal drug delivery system. Pharm Res. 2002, 19:1097-1104.
58. Dyer AM, Hinchcliffe M, Watts P, et al. Nasal delivery of Insulin using novel chitosan based formulations: A comparative study in two animal models between simple chitosan formulations and chitosan nanoparticles. Pharm Res. 2002, 19: 998-1008.
59. Klas S, Petrie C, Warwood S, et al. A single immunization with a dry powder anthrax vaccine protects rabbits against lethal aerosol challenge. Vaccine. 2008,26:5494-5502.
60. Gavini E, Hegge AB, Rassu G, et al. Nasal administration of Carbamazepine using chitosan microspheres: In vitro/in vivo studies. Int J Pharm. 2006, 307: 9-15.
61. Sinha VR, SinglaAK, Wadhawan S, et al. Chitosan microspheres as a potential carrier for drugs. Int J Pharm. 2004, 274: 1-33.
62. Dalpiaz A, Gavini E, Colombo G, et al. Brain Uptake of an Anti-Ischemic Agent by Nasal Administration of Microparticles. J Pharm Sci. 2008, 97: 4889-4903.
63. Wang LY, Gu YH, Su ZG, et al. Preparation and improvement of release behavior of chitosan microspheres containing insulin. Int J Pharm. 2006, 311:187-195
64. Rassu G, Gavini E, Jonassen H, et al. New Chitosan Derivatives for the Preparation of Rokitamycin Loaded Microspheres Designed for Ocular or Nasal Administration. J Pharm Sci. 2009, 98:4852-4865.
65. Lim ST, Martin GP, Berry DJ, et al. Preparation and evaluation of the in vitro drug release properties and mucoadhesion of novel microspheres of hyaluronic acid and chitosan.J Control Release. 2000, 66: 281-292.
66. Alhalaweh A, Andersson S, Velaga SP. Preparation of zolmitriptan-chitosan microparticles by spray drying for nasal delivery. Eur J Pharm Sci. 2009, 38:206-214.
67. Jiang HL, Kang ML, Quan JS, et al. The potential of mannosylated chitosan microspheres to target macrophage mannose receptors in an adjuvant-delivery system for intranasal immunization. Biomaterials. 2008, 29:1931-1939.
68. Illum L. Nanoparticulate systems for nasal delivery of drugs: A real improvement over simple systems? J Pharm Sci. 2007, 96:473-483.
69. Brooking J, Davis SS, Illum L. Transport of nanoparticles across the rat nasal mucosa. J Drug Target. 2001, 9: 267-279.
70. Amidi M, Romeijn SG, Borchard G, et al. Preparation and characterization of protein-loaded N-trimethyl chitosan nanoparticles as nasal delivery system, J Control Release. 2006, 111: 107-116.
71. Wang X, Zheng C, Wu Z, et al. Chitosan-NAC nanoparticles as a vehicle for nasal absorption enhancement of insulin. J Biomed Mater Res B. 2009, 88:150-161.
72. Mistry A, Stolnik S, Illum L. Nanoparticles for direct nose-to-brain delivery of drugs. Int J Pharm. 2009, 379:146-157.
73. Wang X, Chi N, Tang X. Preparation of estradiol chitosan nanoparticles for improving nasal absorption and brain targeting. Eur J Pharm Biopharm. 2008,70:735-740.
74. Al-Ghananeem AM, Saeed H, Florence R, et al. Intranasal drug delivery of didanosine-loaded chitosan nanoparticles for brain targeting; an attractive route against infections caused by aids viruses. J Drug Target. 2010,18:381-388.
75. Haque S, Shadab M, Fazil M, et al. Venlafaxine loaded chitosan NPs for brain targeting: Pharmacokinetic and pharmacodynamic evaluation. Carbohyd Polym.2012, 89:72-79.
76. Dyer AM, Hinchcliffe M, Watts P, et al. Nasal Delivery of Insulin Using Novel Chitosan Based Formulations: A Comparative Study in Two Animal Models Between Simple Chitosan Formulations and Chitosan Nanoparticles. Pharm Res. 2002, 19: 998-1008.
77. Kreuter J. Nanoparticle systems for brain delivery of drugs. Adv Drug Deliv Rev. 2001,47:65-81
78. Schipper NGM, Vårum KM, Artursson P. Chitosans as absorption enhancers for poorly absorbable drugs. 1: Influence of molecular weight and degree of acetylation on drug transport across human intestinal epithelial (Caco-2) cells. Pharm Res. 1996,13:1686-1692.
79. Boonyo W, Junginger HE, Waranuch N, et al. Chitosan and trimethyl chitosan chloride (TMC) as adjuvants for inducing immune responses to ovalbumin in mice following nasal administration, J Control Release. 2007, 121: 168-175.
80. Na L, Mao S, Wang J, et al. Comparison of different absorption enhancers on the intranasal absorption of isosorbidedinitrate in rats. Int J Pharm 2010, 397:59-66.
81. Mao S, Shuai X, Unger F, et al. The depolymerization of Chitosan, Effects on physicochemical and biological properties. Int J Pharm. 2004, 281: 45-54.
82. Alsarra IA, Betigeri SS, Zhang H, et al. Molecular weight and degree ofdeacetylation effects on lipase-loaded chitosan bead characteristics. Biomaterials. 2002, 23: 3637-3644.
83. Huang M, Khorb E, Lim LY. Uptake and cytotoxicity of chitosan molecules and nanoparticles: effects of molecular weight and degree of deacetylation. Pharm Res. 2004, 21: 344-353.
84. Zhang H, Neau SH. In vitro degradation of chitosan by a commercial enzyme preparation: effect of molecular weight and degree of deacetylation. Biomaterials. 2001, 22: 1653-1658.
85. Sinswatand P, Tengamnuay P. Enhancing effect of chitosan on nasal absorptionof salmon calcitonin in rats: comparison with hydroxypropyl-and dimethyl-β-cyclodextrins. Int J Pharm. 2003, 257:15-22.
86. ECCLESTON GM, HUDSONNE. The use of a capillary rheometer to determine the shear and extensional flow behaviour of nasal spray suspensions. J Pharm Pharmacol. 2000, 52:1223-1232.
87. Charlton ST, Davis SS, Illum L. Evaluation of bioadhesive polymers as delivery systems for nose to brain delivery: In vitro characterisation studies. J Controll Release. 2007,118:225-234.
88. Kotzé AF, Luessen HL, De Boer AG, et al. Chitosan for enhanced intestinal permeability: prospects for derivatives soluble in neutral and basic environment. Eur J Pharm Sci. 1998a, 7: 145-151.
89. Atyabi F, Moghaddam FA, Dinarvand R, et al. Thiolated chitosan coated poly hydroxyethyl methacrylate nanoparticles: Synthesis and characterization. CarbohydPolym. 2008, 74: 59-67.
90. Roldo M, Hornof M, Caliceti P, et al. Mucoadhesivethiolatedchitosans as platforms for oral controlled drug delivery: synthesis and in vitro evaluation. Eur J Pharm Biopharm. 2004, 57:115-121.
91. Mo R, Xiao Y, Sun M, et al. Enhancing effect of N-octyl-O-sulfate chitosan on etoposide absorption. Int J Pharm. 2011,4090:38-45.
92. Bernkop-Schnürch A, Hornof M, Guggi D. Thiolated chitosans. Eur J Pharm Biopharm. 2004,57: 9-17.
93. Hornof MD, Kast CE, Bernkop-Schnürch A. In vitro evaluation of the viscoelastic behavior of chitosan - thioglycolic acid conjugates. Eur J Pharm Biopharm. 2003, 55: 185-190.
94. Mao S, Shuai X, Unger F, et al. Synthesis, characterization and cytotoxicity of poly(ethylene glycol)-graft-trimethyl chitosan block copolymers. Biomaterials. 2005, 26: 6343-6356.
95. Kotzé AF, Lue HL, En BJ, et al. Comparison of the effect of different chitosan salts and N-trimethyl chitosan chloride on the permeability of intestinal epithelial cells (Caco-2).J Control Release. 1998, 51: 35-46.
96. Chen H, Wu J, Sun M, et al. N-trimethyl chitosan chloride-coated liposomes for the oral delivery of curcumin. J Liposome Res. 2012, 22:100-109.
97. Boonyo W, Junginger HE, Waranuch N, et al. Chitosan and trimethyl chitosan chloride (TMC) as adjuvants for inducing immune responses to ovalbumin in mice following nasal administration. J Control Release. 2007,121:168-175.
98. Hamman JH, Stander M, Kotze AF. Effect of the degree of quaternization of N-trimethyl chitosan chloride on absorption enhancement: in vivo evaluation in rat nasal epithelia. Int J Pharm. 2002, 232: 235-42.
99. Snyman D, Hamman JH, Kotze AF. Evaluation of the mucoadhesive properties of N-trimethyl chitosan chloride. Drug DevInd Pharm 2003;29:61-69.
100. Thanou M, Verhoef JC, Junginger HE. Oral drug absorption enhancement by chitosan and its derivatives. Adv Drug Deliv Rev. 2001, 52:117-126.
101. Sayi{dotless}n B, Somavarapu S, Li XW, et al. TMC-MCC (N-trimethyl chitosan-mono-N-carboxymethyl chitosan) nanocomplexes for mucosal delivery of vaccines. Eur J Pharm Sci. 2009, 38: 362-369.
102. Sayi{dotless}n B, Somavarapu S, Li XW, et al. Mono-N-carboxymethyl chitosan (MCC) and N-trimethyl chitosan (TMC) nanoparticles for non-invasive vaccine delivery. Int J Pharm. 2008, 363:139-148.
103. Dal Pozzo A, Vanini L, Fagnoni M, et al. Preparation and characterization of poly(ethylene glycol)-crosslinkedreacetylatedchitosans. CarbohydPolym. 2000, 42:201-206.
104. Zhang M, Li XH, Gong YD, et al. Properties and biocompatibility of chitosan films by blending with PEG. Biomaterials. 2002, 23: 2641-2648.
105. Zhang X, Zhang H, Wu Z, et al. Nasal absorption enhancement of insulin using PEG-grafted chitosan nanoparticles. Eur J Pharm Biopharm. 2008, 68: 526-534.
106. Bhattarai N, Ramay HR, Gunn J, et al. PEG-grafted chitosan as an injectable thermosensitive hydrogel for sustained protein release. J Control Release. 2005, 103: 609-624.
107. Harding S,E. Trends in muco-adhesive analysis. Trends Food Sci Tech. 2006, 17:255-262.
108. Bowman K, Leong KW. Chitosan nanoparticles for oral drug and gene delivery. Int J Nanomed. 2006, 1:117.
109. Aspden TJ, Illum L,, Skaugrud Ø. Chitosan as a nasal delivery system: evaluation of insulin absorption enhancement and effect on nasal membrane integrity using rat models. Eur J Pharm Sci. 1996, 4:23-31.
110. Shahiwala A, Misra A. Nasal delivery of levonorgestrel for contraception: An experimental study in rats. Fertil Steril. 2004, 81:893-8.
111. Lim ST, Forbes B, Martin GP, BrownMB. In vivo and in vitro characterization of novel microparticulates based on hyaluronan and chitosan hydroglutamate. AAPS Pharm-SciTech. 2001, 2:20.
112. Krauland AH, Guggi D, Bernkop-Schnürch A. Thiolated chitosan microparticles: a vehicle for nasal peptide drug delivery. Int J Pharm. 2006,307:270-277.
113. Zhang X, Zhang H, Wu Z, et al. Nasal absorption enhancement of insulin using PEG-grafted chitosan nanoparticles. Eur J Pharm Biopharm. 2008,68:526-534.
114. Cheng YH, Dyer AM, Jabbal-Gill I, Hinchcliffe M, Nankervis R, Smith A, et al. Intranasal delivery of recombinant human growth hormone (somatropin) in sheep using chitosan-based powder formulations. Eur J Pharm Sci. 2005, 26:9-15.
115. Vaka SRK, Sammeta S, Day LB, et al. Delivery of nerve growth factor to brain via intranasal administration and enhancement of brain uptake. J Pharm Sci. 2009,98: 3640-3646.
116. Khan S, Patil K, Yeole P, et al. Brain targeting studies on buspirone hydrochloride after intranasal administration of mucoadhesive formulation in rats. J Pharm Pharm. 2009, 61:669-675.
117. Klas S, Petrie C, Warwood S, et al. A single immunization with a dry powder anthrax vaccine protects rabbits against lethal aerosol challenge. Vaccine. 2008, 26:5494-5502.
118. Günbeyaz M, Faraji A, Özkul A, et al. Chitosan based delivery systems for mucosal immunization against bovine herpesvirus 1 (BHV-1). Eur J Pharm Sci.2010, 41:531-545.
119. Kang ML, Jiang HL, Kang SG, et al. Pluronic ® F127 enhances the effect as an adjuvant of chitosan microspheres in the intranasal delivery of Bordetella bronchiseptica antigens containing dermonecrotoxin. Vaccine. 2007, 25:4602-4610.
120. Khatri K, Goyal AK, Gupta PN, et al. Plasmid DNA loaded chitosan nanoparticles for nasal mucosal immunization against hepatitis B. Int J Pharm.2008, 354:235-241.
121. Prego C, Paolicelli P, Díaz B, et al. Chitosan-based nanoparticles for improving immunization against hepatitis B infection. Vaccine. 2010, 28:2607-2614